Yoshida J, Kajita Y, Wakabayashi T, Sugita K
Department of Neurosurgery, Nagoya University School of Medicine, Japan.
Acta Neurochir (Wien). 1994;127(1-2):55-9. doi: 10.1007/BF01808547.
We analysed long-term follow-up results of 175 patients with malignant glioma (110 glioblastoma and 65 anaplastic astrocytoma) treated under five different regimes during the past two decades. The factors of age (less than 40), histology (anaplastic astrocytoma) and type of adjuvant therapy (radiation and chemotherapy) contributed to long survival. The other important factor was the response to adjuvant therapy. Cases of gross total removal or complete response (CR) of a residual tumour to an adjuvant therapy showed a better prognosis. The three and five year survival rate was 42% and 24%, respectively. The highest CR ratio (23%) was seen in patients treated by intravenous injection of interferon and ACNU in addition to radiotherapy (IAR therapy).
我们分析了过去二十年间在五种不同治疗方案下接受治疗的175例恶性胶质瘤患者(110例胶质母细胞瘤和65例间变性星形细胞瘤)的长期随访结果。年龄(小于40岁)、组织学类型(间变性星形细胞瘤)和辅助治疗类型(放疗和化疗)等因素对长期生存有影响。另一个重要因素是对辅助治疗的反应。肿瘤大体全切或残余肿瘤对辅助治疗达到完全缓解(CR)的病例预后较好。三年和五年生存率分别为42%和24%。在接受放疗的基础上静脉注射干扰素和ACNU治疗的患者(IAR治疗)中,CR率最高(23%)。